Exploring the potential of the SGLT2 inhibitor dapaglif lozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 412-419

  Henry, Robert R ^a,b   Rosenstock, Julio ^c   Edelman, Steven ^a,b   Mudaliar, Sunder ^a,b   Chalamandaris, Alexandros Georgios ^d   Kasichayanula, Sreeneeranj ^d   Bogle, Allyson ^d   Iqbal, Nayyar ^d   List, James ^d   Griffen, Steven C ^d  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC EXCURSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH PARESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VAGINA MYCOSIS; VAGINITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; HYPERGLYCEMIA; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; GLYCOSURIA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PILOT PROJECTS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84934442921     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2955     Document Type: Article

References (8)

1. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: Results from the T1D exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411- 3419.
2. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetesdcauses, effects and coping strategies. Diabetes Obes Metab 2007; 9:799-812.
3. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007;30:707- 712.
4. Wilding JP, Woo V, Soler NG, et al.; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 2012;156:405- 415.
5. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; for the Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years. Diabetes Obes Metab 1 August 2013 [Epub ahead of print].
6. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28:101-109.
7. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:357- 365.
8. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-519.